after creating an aerosol mist of the powder. Technology for carrying such out is described within U.S. Patent 5,775,320, issued July 7, 1998 and U.S. Patent 5,740,794 issued April 21, 1998.

IN THE CLAIMS

Please cancel original claims 1-27 without prejudice to renewal.

Please enter new claims 28-42 as shown below.

28. (New) A pharmaceutical formulation for treatment of airway mucus hypersecretion, comprising:

a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist in an amount sufficient to reduce airway mucus hypersecretion; and

a flowable formulation suitable for delivery by inhalation.

29. (New) The pharmaceutical formulation of claim 28, wherein the EGF-R antagonist is formulated with a fluid carrier and a propellant.

30. (New) The pharmaceutical formulation of claim 28, wherein the EGF-R antagonist is formulated in an aqueous or an ethanolic solution.

31. (New) The pharmaceutical formulation of claim 28, wherein the EGF-R antagonist is in a dry powder formulation.

32. (New) The formulation of claim 29, wherein said formulation is aerosolized to create an aerosol.

33. (New) The formulation of claim 28, further comprising an agent selected from the group consisting of a bronchiodilator, a corticosteroid, an expectorant, and a mucolytic agent.

34. (New) A package for use in treating airway mucus hypersecretion, comprising a container having therein a flowable formulation comprising a pharmaceutically active epidermal growth factor receptor (EGF-R) antagonist.

B3

13. ~~10~~. (Amended) An aerosol comprising a pharmaceutically active epidermal growth factor receptor (EGF-R) antagonist that binds an EGF-R, wherein the EGF-R is present in the aerosol in an amount effective to reduce airway mucus hypersecretion.

8 ~~35.~~ (New) The package of claim ~~34~~ 7, wherein the package is a metered dose inhaler, and the EGF-R antagonist is formulated with a propellant.

9 ~~36.~~ (New) The package of claim ~~35~~ 8, wherein particles having a diameter of about 0.5 to 12 microns are generated when the formulation is aerosolized.

10 ~~37.~~ (New) The package of claim ~~34~~ 7, wherein the package is a dry powder inhaler, and the EGF-R antagonist is formulated in a dry powder formulation.

14 (cont'd)

11 ~~38.~~ (New) The package of claim ~~34~~ 7, wherein the package is a nebulizer, and the EGF-R antagonist is in an aqueous or ethanolic solution.

12 ~~39.~~ (New) The package of claim ~~34~~ 7, wherein the formulation further comprises an agent selected from the group consisting of a bronchodilator, a corticosteroid, an expectorant, and a mucolytic agent.

~~Sub B~~ 13 ~~40.~~ (New) An aerosol comprising a pharmaceutically active epidermal growth factor receptor (EGF-R) antagonist.

14 ~~41.~~ (New) The aerosol of claim ~~40~~ 13, wherein the EGF-R antagonist is contained within aerosolized particles having a diameter in a range of from about 0.25 micron to about 12 microns.

15 ~~42.~~ (New) The aerosol of claim ~~40~~ 13, further comprising an agent selected from the group consisting of a bronchodilator, a corticosteroid, an expectorant, and a mucolytic agent.

II. REMARKS

Formal Matters

Claims 28-42 are pending after entry of the amendments set forth herein.

Originally filed claims 1-27 are canceled without prejudice to renewal.

New claims 28-42 are added. Support for new claims 28-40 is found in the claims as originally filed, and throughout the specification, e.g. on page 17, line 23 to page 19, line 16, and including at the